At TCT, A New Vision of the Device Industry
Executive Summary
The biggest news at this year's TCT meeting was, as anticipated, Boston Scientific's release of its latest TAXUS drug-eluting stent trial results, which showed slightly better binary restenosis rates than Johnson & Johnson's SIRIUS trial. The TAXUS results appeared to trigger a 4.5% drop in J&J's share price, surprising given that the TAXUS results weren't a dramatic improvement, but indicative of how much the companies involved with DES have at stake.